Weight gain and metabolic disorders in schizophrenia;Ganho de peso e alterações metabólicas em esquizofrenia

Revista de Psiquiatria Clinica

Volumn 34, Issue SUPPL. 2, 2007, Pages 184-188

  Leitão Azevedo, Carmem Lucia ^a   Guimarães, Lísia Rejane ^d   Lobato, Maria Inês ^a   Belmonte De Abreu, Paulo ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Engenheiro Alvaro Nunes Pereira   (Brazil)

^d NONE

Author keywords

Metabolic disturbances; Schizophrenia; Weight gain

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIFE EXPECTANCY; MEDLINE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 36949016251     PISSN: 01016083     EISSN: 1806938X     Source Type: Journal    
DOI: 10.1590/S0101-60832007000800007     Document Type: Review

References (21)

1. Allison, D.B.; Mentore, J.L.; Heo, M.; Chandler, L.P.; Cappelleri, J.C.; Infante, M.C. et al. - Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999a.
2. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596-601, 2004.
3. Baptista, T. - Body weight gain induced by antipsychotic drug: mechanisms and management. Acta Psychiatr Scand 100:3-16, 1999.
4. Bobes, J.; Arango, P.; Carmena, R.; Garcia-Garcia, M.; Rejas, J. - Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 90:162-173, 2007.
5. Departamentos de Aterosclerose, Cardiologia Clínica e FUNCOR da Sociedade Brasileira de Cardiologia. Diretrizes para Cardiologistas sobre Excesso de Peso e Doença Cardiovascular. Arq Bras Cardiologia 78 (Suppl 1), 2002.
6. Goff, D.C.; Cather, C.; Evins, E.; Henderson, D.C.; Freudenreich, O.; Copeland, P.M. et al. - Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66:183-194, 2005.
7. Heiskanen, T.; Niskanen, L.; Lyytikainen, R.; Saarinen, P.I.; Hintikka, J. - Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64: 575-579, 2003.
8. Henderson, D.C.; Cagliero, E.; Gray, C.; Nasrallah, R.A.; Hayden, D.L.; Schoenfeld, D.A.; Goff, D.C. - Clozapine: diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-971, 2000.
9. Leitão-Azevedo, C.L.; Abreu, M.G.B.; Guimarães, L.R.; Moreno, D.; Lobato, M.I.; Gama, C.S. et al. - Sobrepeso e obesidade em pacientes esquizofrênicos em uso de clozapina comparado ao uso de outros antipsicóticos. Revista Psiquiatria 28(2):12-18, 2006a.
10. Leitão-Azevedo, C.L.; Guimarães, L.R.; Abreu, M.G.B.; Gama, C.S.; Lobato, M.I.; Belmonte-de-Abreu, P. S. - Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatria 28(4):301-304, 2006b.
11. Meyer, J.M. - Schizophrenia and the metabolic syndrome. Medscape Psychiatry & Mental Health, 8(1): 2005. Disponível em: http://www.medscape.com/viewarticle/506136
12. Meyer, J.M.; Koro, C.E. - The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70:1-17, 2004.
13. Ministério da Saúde. Fundação Nacional da Saúde. Datasus. Sistema de Informação sobre mortalidade 1979-1998: dados de declaração de óbito. Brasília, 2000.
14. Newman, S.C.; Bland R.C. - Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36(4): 239-245,1991.
15. Newcomer, JW. - Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 (Sppl 1): 20-27, 2007.
16. Osser, D.N.; Najarian, D.M.; Dufresne, R.L. - Olanzapine increase weight and serum triglycerides. J Clin Psychiatry 60:767-770,1999.
17. Ryan M.C.M.; Thakore, J.H. - Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Sciences 71:239-257, 2002.
18. Ryan, M.C.M.; Collins, P.; Thakore, J.H. - Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160: 284-289, 2003.
19. Thakore, J.H.; Mann, J.N.; Vlahos, I.; Martin, A.; Reznek, R. - Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26: 137-141, 2002.
20. Wirshing, D.; - Esquizofrenia e obesidade: impacto dos medicamentos antipsicóticos. J Clin Psychiatry 65 (Suppl 18): 2004.
21. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica (I-DBSM). SBH, 2005.